Cartalax: A Literature Course in Six Modules

Cartalax is a name applied to the synthetic tripeptide alanyl-glutamyl-aspartate (AED, Ala-Glu-Asp), one of a family of very short peptides described in the literature as "peptide bioregulators" or "epigenetic regulators". Most indexed papers refer to the amino-acid sequence (AED) rather than the trade-style name, so this course follows the sequence through the peer-reviewed record. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here is a protocol, a recommendation, or a statement that any outcome will occur in a person.

The course is organised in six modules. Each module ends with an explicit statement of the limits of the evidence, because for this compound the limits are as informative as the findings.

Module 1 — What Cartalax Is and How It Has Been Studied

Definition and class

Cartalax belongs to a group of di-, tri- and tetrapeptides developed and investigated within a single research tradition, most associated with the St Petersburg Institute of Bioregulation and Gerontology. Members of this family that appear in the verified literature include the tetrapeptide AEDG (studied under the name Epitalon), the tripeptides EDR, KED and AED, and the dipeptide KE. A 2025 review described AEDG as a pineal-derived tetrapeptide with a wide range of reported biological activities in experimental systems (PMID 40141333), and that review is useful context for how this class is framed by its investigators.

Origin

The class originated from work on extracts of animal tissues: complexes of peptides and proteins were isolated from organs, tested, and then reduced to short synthetic sequences thought to carry the activity. A 2020 paper illustrated that methodology directly, characterising the structural features and chaperone-like activity of a peptide–protein complex isolated from cattle sclera (PMID 33294633). The synthetic short peptides that followed were positioned by their authors as tissue-associated regulators, an idea set out in an early paper on tissue-specific effects of peptides (PMID 11713572). The "cart-" naming convention reflects an intended association with cartilage tissue, but the association is a framing used by the developers rather than a demonstrated tissue-targeting property in the papers listed here.

Forms and how it appears in studies

In the experimental literature AED and its relatives appear as synthetic peptides dissolved in culture medium and added to cells, or as solutions given to laboratory animals. Researchers most often report the amino-acid sequence, the concentration used in culture, and the number of passages or days of exposure. There is no approved human dosage form described in any of the verified papers.

Limits of the evidence (Module 1)

• The name "Cartalax" is largely absent from indexed abstracts; the traceable entity is the sequence AED.
• Much of the foundational work comes from a small number of affiliated groups, and independent replication outside that tradition is sparse in the verified set.
• Tissue-origin framing (cartilage) is not itself tested in the papers cited above.

Module 2 — Mechanism as Described in the Literature

The mechanistic account offered by this research group is epigenetic. A 2016 review argued that short peptides can penetrate cells and nuclei and interact with DNA and histone proteins, thereby regulating gene expression (PMID 27909961). In that framework, a tripeptide such as AED is not a receptor agonist in the classical pharmacological sense but is proposed to act as a small ligand influencing transcription of particular genes.

A 2021 Russian-language review extended the same reasoning to adaptation, discussing epigenetic regulation of adaptogenesis in the context of pathology and ageing (PMID 33993656). A 2021 study in Pharmaceuticals applied the concept in vivo, reporting neuroprotective effects of tripeptides described as epigenetic regulators in a mouse model of Alzheimer's disease (PMID 34071923). Related work on the tetrapeptide AEDG reported effects on telomere length and mitotic index in phytohaemagglutinin-stimulated human blood lymphocytes, an endpoint the authors linked to proliferative capacity (PMID 31761987).

What the mechanism papers actually demonstrate

The mechanistic literature is largely a combination of modelling arguments, in vitro observations of changed expression of selected markers, and reviews by the same authors who generated the primary data. Direct structural evidence of a specific tripeptide–DNA interaction driving a specific physiological outcome in a living human is not present in the verified set.

Limits of the evidence (Module 2)

• Proposed gene-regulatory mechanisms rest heavily on review articles rather than independent structural or genome-wide studies (PMID 27909961).
• Mechanistic work on AEDG and other sequences is frequently extrapolated to AED; the sequences are not interchangeable.
• No verified paper traces a mechanism from peptide administration to a clinical endpoint in humans.

Module 3 — Reported Outcomes by Study

The table below summarises the models, endpoints and reported results in the verified papers most relevant to AED and its immediate relatives. None of these findings is a statement about what would happen in a person, and none is presented here as a benefit.

Reading the outcome literature carefully

Three features recur. First, most endpoints are cellular markers — proliferation, expression of selected proteins, passage-number tolerance — rather than clinical outcomes such as pain, function, imaging change or survival. Second, several frequently cited results concern peptides other than AED, including AEDG (PMID 31761987) and EDL (PMID 28744634), and are sometimes presented elsewhere as though they described AED. Third, comparative designs are uncommon; the 2020 comparison of KE and AED in fibroblasts is a partial exception (PMID 33231794).

Limits of the evidence (Module 3)

• No randomised controlled human trial of AED appears in the verified set.
• Cell-culture concentrations do not translate into human exposure, and no verified paper makes that bridge.
• Cartilage, joint and connective-tissue clinical endpoints — the outcomes most often associated with the Cartalax name in non-scientific writing — are not tested in any verified paper.

Module 4 — Cartalax Side Effects: What Studies Report

The honest summary is that the verified literature contains almost no adverse-event data for AED, because the studies were not designed to generate any. The fibroblast and stem-cell experiments were in vitro investigations of cell behaviour, and the published reports centred on markers of ageing and functional activity rather than on toxicity screening or safety monitoring (PMID 33231794, PMID 31677028). In cultured systems there is no organism in which a systemic adverse event could be observed.

In the animal work, the reported framing was protective rather than harmful: the 2015 renal study reported restoration of kidney functional measures after cisplatin injury (PMID 26515176), the 2017 paper reported a nephroprotective effect of the EDL peptide in acute kidney injury (PMID 28744634), and the 2021 mouse study reported neuroprotective outcomes for tripeptide epigenetic regulators (PMID 34071923). Those abstracts described efficacy-type endpoints; they are not substitutes for formal toxicology, and an absence of reported harms in a small efficacy study is not evidence of safety.

The 2025 review of AEDG discussed the peptide's bioactivity profile in experimental systems (PMID 40141333), and even for that better-documented relative the review literature does not supply a human adverse-event dataset comparable to what a regulator would require.

Limits of the evidence (Module 4)

• No verified paper reports a structured safety population, adverse-event tabulation, or dose-limiting toxicity for AED.
• Long-term exposure, immunogenicity, reproductive effects and carcinogenicity are untested in the verified set.
• Injectable material of unverified purity carries risks — contamination, endotoxin, incorrect identity — that are properties of the product rather than the molecule and are not addressed in any of these papers.

Module 5 — Pharmacokinetics Where Data Exist

For AED specifically, the verified literature contains no absorption, distribution, metabolism or excretion study: no plasma concentration–time curve, no half-life, no bioavailability figure, no tissue distribution data in humans. What exists instead is a conceptual claim about cellular entry. The 2016 review argued that short peptides can cross cell and nuclear membranes to reach DNA and histones, which is the pharmacokinetic assumption underlying the whole class (PMID 27909961).

General peptide chemistry makes several expectations reasonable, though they are not measured for AED in these sources: very short peptides are susceptible to peptidase cleavage, and their constituent amino acids re-enter normal metabolism. The 2025 AEDG review remains the closest thing in the verified set to a consolidated pharmacological overview for this family, and it is a review of a different sequence (PMID 40141333). The 2020 sclera peptide–protein complex paper described structural characterisation of a tissue-derived preparation rather than in-vivo kinetics (PMID 33294633).

Limits of the evidence (Module 5)

• No human or animal PK parameters for AED appear in the verified papers.
• Claims about how long the peptide "lasts" or how it distributes cannot be sourced to this literature.
• Route comparisons (oral, sublingual, parenteral) are not studied in the verified set.

Module 6 — Regulatory Status, Stated Factually

Cartalax/AED is not an approved medicine in the United States: there is no FDA-approved drug product containing this tripeptide, and it has not been reviewed through a new drug application. It is not an approved medicinal product in the European Union either. Material offered under the Cartalax name in Western markets is typically labelled "research use only" (RUO), a designation meaning the substance is supplied for laboratory work and is not intended for human or veterinary use; RUO labelling is not an approval and carries no assurance of identity, sterility or purity beyond the supplier's own claims.

In the compounding context, US pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may generally compound only from bulk drug substances that meet specified criteria, and FDA has placed a number of peptide substances in the category of ingredients raising significant safety concerns pending further evaluation. Practically, that means peptides without an approved application, a USP monograph, or inclusion on the relevant bulks lists are not straightforwardly compoundable in the United States.

Regulatory treatment differs by country; in some jurisdictions related peptide preparations have historically been marketed under different frameworks, which is one reason the research literature and the commercial landscape diverge. This is general information, not legal advice; regulations change and enforcement varies, and a qualified professional should be consulted for any specific situation.

Limits of the evidence (Module 6)

• Regulatory classification says nothing about biological activity in either direction.
• The absence of approval reflects the absence of submitted clinical evidence, not a formal finding of harm.
• Product-level status can change; the scientific record summarised above does not change with it.

What the Studies Did Not Test

Closing a course on this compound requires naming the gaps plainly. Across the verified literature, researchers did not test:

1. Human clinical outcomes. No controlled trial in people with any condition appears in this set; the strongest in-vivo data are animal models such as the Alzheimer's mouse work (PMID 34071923) and the renal injury models (PMID 26515176).
2. Joint, cartilage or musculoskeletal endpoints in humans. Despite the name, no verified paper reported cartilage imaging, joint function or pain outcomes.
3. Dose–response in humans. No verified paper established a human dose, schedule or route, and the cell-culture concentrations reported in the fibroblast studies cannot be converted into one (PMID 27259496, PMID 33231794).
4. Safety over time. Chronic dosing, interaction with medicines, and effects in pregnancy, in children or in organ impairment are absent from the verified set.
5. Head-to-head comparison with standard care. No study contrasted AED with an established therapy for any indication.
6. Independent replication at scale. Most findings originate within one research tradition, including the reviews that interpret them (PMID 27909961, PMID 33993656).

A reader finishing this course should be able to distinguish three different statements: that a tripeptide changed a marker in cultured cells; that a related peptide changed an outcome in a rodent model; and that a compound does something useful in a human being. Only the first two are supported anywhere in the verified literature, and the third is not claimed here. Again, this page is educational only and is not medical advice; decisions about any substance belong with a licensed physician.

References

• Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties (International Journal of Molecular Sciences, 2025)
• Short Peptides Regulate Gene Expression (Bulletin of Experimental Biology and Medicine, 2016)
• Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Bulletin of Experimental Biology and Medicine, 2019)
• Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure (Bulletin of Experimental Biology and Medicine, 2015)
• Short Peptides Protect Oral Stem Cells from Ageing (Stem Cell Reviews and Reports, 2020)
• Peptide-protein complex from cattle sclera: Structural aspects and chaperone activity (Biochemistry and Biophysics Reports, 2020)
• Epigenetic regulation of adaptogenesis by pathology and aging (Advances in Gerontology, 2021)
• Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease (Pharmaceuticals, 2021)
• Tissue-specific effects of peptides (Bulletin of Experimental Biology and Medicine, 2001)
• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro (Bulletin of Experimental Biology and Medicine, 2016)
• Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Bulletin of Experimental Biology and Medicine, 2017)
• Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging (Bulletin of Experimental Biology and Medicine, 2020)